FOR IMMEDIATE RELEASE
ACS News Service Weekly PressPac: June 09, 2021
Creating a needle-free COVID-19 vaccine
“Intranasal vaccines aim to stop COVID-19 where it starts”
Chemical & Engineering News
Vaccines are mostly synonymous with needles, an efficient and effective way to provide immunity to myriad infections. As COVID-19 vaccination efforts roll out across the U.S. and the world, some experts believe that a vaccine administered through the nose could be just as effective and easier to administer. A cover story in Chemical & Engineering News, the weekly newsmagazine of the American Chemical Society, explains the pros and cons of nasal vaccines.
SARS-CoV-2, the virus that causes COVID-19, often enters the body through the nose when a person inhales. From there it encounters a network of mucosal membranes that form the body’s first line of immune defense, writes Associate Editor Ryan Cross. The cells of mucus membranes create a special type of antibody, which experts say can provide both mucosal and systemic immunity when triggered by a vaccine that is sprayed into the nasal cavity. In contrast, injectable vaccines only trigger a systemic immune response. The COVID-19 vaccines currently available in the U.S. and Europe are highly effective, but there is not enough supply to inoculate the entire world. So, an intranasal version could help offset the disparity, on top of being easier to use.
However, the mucosal immune system is difficult to study, and intranasal vaccines have not generated much interest in recent years. Only one intranasal vaccine (AstraZeneca’s FluMist) has come to market in the U.S., but its higher cost and mixed results compared to the typical flu shot have made it unpopular. In addition, the way the vaccine is administered means that a patient could sneeze out part of it before it’s absorbed by the body, making it unclear how much of the dose a person gets. Despite these challenges, scientists and biotech companies are still working to make intranasal vaccines for respiratory illnesses. The pandemic has provided an opportunity to run clinical trials, and at least one company hopes to manufacture and distribute nasal doses of the COVID-19 vaccine by the end of the year.
The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS’ mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and all its people. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive press releases from the American Chemical Society, contact firstname.lastname@example.org.
Note: ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies.